T cell dysfunction by hepatitis C virus core protein involves PD-1/PDL-1 signaling

Viral Immunology

Volumn 20, Issue 2, 2007, Pages 276-287

  Yao, Zhi Q ^a,b   King, Ellis ^a   Prayther, Deborah ^a   Yin, Deling ^a   Moorman, Jonathan ^a,b  

^a East Tennessee State University   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q RECEPTOR; COMPLEMENT RECEPTOR; CORE PROTEIN; INHIBITOR PROTEIN; PROGRAMMED DEATH 1; PROGRAMMED DEATH LIGAND 1; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; PERSISTENT VIRUS INFECTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; VIRUS CORE;

ANTIGENS, CD; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MEMBRANE GLYCOPROTEINS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, COMPLEMENT; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VIRAL CORE PROTEINS;

HEPATITIS C VIRUS;

EID: 34447523803     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.0096     Document Type: Article

References (38)

1. Balasubramanian A, Ganju RK, and Groopman JE: Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes. J Biol Chem 2003;278:35755-35766.
2. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, and Ahmed R: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-687.
3. Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, Heinrich PC, and Haussinger D: IFN-( antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 2003;17:488-490.
4. Chen A, Gaddipati S, Hong Y, Volkman DJ, Peerschke EI, and Ghebrehiwet B: Human T cells express specific binding sites for C1q: Role in T cell activation and proliferation. J Immunol 1994;153:1430-1440.
5. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, and Walker BD: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006;443:350-354.
6. Eisen-Vandervelde AL, Yao ZQ, and Hahn YS: The molecular basis of HCV-mediated immune dysregulation. Clin Immunol 2004;111:16-21.
7. Freeman GJ, Wherry EJ, Ahmed R, and Sharpe AH: Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 2006;203:2223-2227.
8. + T-cell response in acute hepatitis C. Gastroenterology 1999;117:933-941.
9. Ghebrehiwet B, Lim BL, Kumar R, Feng X, and Peerschke EI: gC1q-R/p33, a member of a new class of multifunctional and mulficompartmental cellular proteins, is involved in inflammation and infection. Immunol Rev 2001;180:65-77.
10. Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, Bhan AK, Andersen J, and Koziel MJ: Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS 2005;19:767-773.
11. + T cells with viral clearance in acute hepatitis C. J Infect Dis 2000;181:1528-1536.
12. + T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 1999;96:5692-5697.
13. Iwai Y, Terawaki S, Ikegawa M, Okazaki T, and Honjo T: PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 2003;198:39-50.
14. Khoury SJ, and Sayegh MH: The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 2004;20:529-538.
15. Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, and Hahn YS: Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest 2000;106:1239-1249.
16. Large MK, Kittlesen DJ, and Hahn YS: Suppression of host immune response by the core protein of hepatitis C virus: Possible implications for hepatitis C virus persistence. J Immunol 1999;162:931-938.
17. Lauer GM, and Walker BD: Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
18. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, and Walker BD: Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-1512.
19. + T cells. J Immunol 2004;172:1744-1753.
20. Maillard P, Krawczynski K, Nitkiewicz J, Bronnert C, Sidorkiewicz M, Gounon P, Dubuisson J, Faure G, Crainic R, and Budkowska A: Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J Virol 2001;75:8240-8250.
21. Manns M, and Rambusch E: Autoimmunity and extrahepatic manifestations of hepatitis C infection. J Hepatol 1999;31(Suppl 1):S39-S42.
22. Masalova OV, Atanadze SN, Samokhvalov EI, Petrakova NV, Kalinina TI, Smirnov VD, Khudyakov YE, Fields HA, and Kushch AA: Detection of hepatitis C virus core protein circulating within different virus particle populations. J Med Virol 1998;55:1-6.
23. Moorman J, Joo M, and Hahn Y: Evasion of host immune surveillance by hepatitis C virus: Potential roles in viral persistence. Arch Immunol Ther Exp (Warsz) 2001;49:189-194.
24. Moorman JP, Prayther D, McVay D, Hahn YS, and Hahn CS: The C-terminal region of hepatitis C core protein is required for Fas-ligand independent apoptosis in Jurkat cells by facilitating Fas oligomerization. Virology 2003;312:320-329.
25. Nishimura H, and Honjo T: PD-1: An inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001;22:265-268.
26. Par G, Berki T, Palinkas L, Balogh P, Szereday L, Halasz M, Szekeres-Bartho J, Miseta A, Hegedus G, Mozsik G, Hunyady B, and Par A: [Immunology of HCV infection: The causes of impaired cellular immune response and the effect of antiviral treatment]. Orv Hetil 2006;147:591-600.
27. + T cell survival in HIV infection. J Exp Med 2006;203:2281-2292.
28. Ray RB, and Ray R: Hepatitis C virus core protein: Intriguing properties and functional relevance. FEMS Microbiol Lett 2001;202:149-156.
29. + T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003;197:1645-1655.
30. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, and Rehermann B: Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6:578-582.
31. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, and Chisari FV: Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-1406.
32. + T cells leads to reversible immune dysfunction. Nat Med 2006;12:1198-1202.
33. Vogel A, Manns MP, and Strassburg CP: Autoimmunity and viruses. Clin Liver Dis 2002;6:739-753.
34. + T cells in chronic hepatitis C virus infection. J Immunol 2002;169:3447-3458.
35. Yao ZQ, Eisen-Vandervelde A, Ray S, and Hahn YS: HCV core/gC1qR interaction arrests T cell cycle progression through stabilization of the cell cycle inhibitor p27Kip1. Virology 2003;314:271-282.
36. + T cells leads to impaired activation of Lck and Akt. J Virol 2004;78:6409-6419.
37. Yao ZQ, Nguyen DT, Hiotellis AI, and Hahn YS: Hepatitis C virus core protein inhibits human T lymphocyte responses by a complement-dependent regulatory pathway. J Immunol 2001;167:5264-5272.
38. Yao ZQ, Ray S, Eisen-Vandervelde A, Waggoner S, and Hahn YS: Hepatitis C virus: Immunosuppression by complement regulatory pathway. Viral Immunol 2001;14:277-295.